PL197186A1 - METHOD OF MAKING STEROIDS - Google Patents

METHOD OF MAKING STEROIDS

Info

Publication number
PL197186A1
PL197186A1 PL19718677A PL19718677A PL197186A1 PL 197186 A1 PL197186 A1 PL 197186A1 PL 19718677 A PL19718677 A PL 19718677A PL 19718677 A PL19718677 A PL 19718677A PL 197186 A1 PL197186 A1 PL 197186A1
Authority
PL
Poland
Prior art keywords
steroids
making
making steroids
Prior art date
Application number
PL19718677A
Other languages
Polish (pl)
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of PL197186A1 publication Critical patent/PL197186A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011—Unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19718677A 1976-04-05 1977-04-04 METHOD OF MAKING STEROIDS PL197186A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB13707/76A GB1581234A (en) 1976-04-05 1976-04-05 11a - amino - 3a - hydroxysteroids

Publications (1)

Publication Number Publication Date
PL197186A1 true PL197186A1 (en) 1979-06-18

Family

ID=10027931

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19718677A PL197186A1 (en) 1976-04-05 1977-04-04 METHOD OF MAKING STEROIDS

Country Status (19)

Country Link
JP (1) JPS52142056A (en)
AU (1) AU517206B2 (en)
BE (1) BE853227A (en)
DE (1) DE2715078A1 (en)
DK (1) DK148677A (en)
ES (1) ES457507A1 (en)
FI (1) FI771046A (en)
FR (2) FR2347382A1 (en)
GB (1) GB1581234A (en)
IE (1) IE45276B1 (en)
IL (1) IL51816A (en)
IT (1) IT1073232B (en)
LU (1) LU77064A1 (en)
NL (1) NL7703667A (en)
NO (1) NO771197L (en)
NZ (1) NZ183775A (en)
PL (1) PL197186A1 (en)
SE (1) SE7703929L (en)
ZA (1) ZA772029B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197725A (en) * 1980-07-16 1984-11-09 Glaxo Group Ltd 11-alpha-aminoandrostanes and pharmaceutical compositions
US4352798A (en) * 1980-07-16 1982-10-05 Glaxo Group Limited 11 α-Amino-androstanes
GB2093846A (en) * 1981-03-02 1982-09-08 Glaxo Group Ltd 11a-amino-3b-hydroxy-androstanes
JPS57203099A (en) * 1981-05-29 1982-12-13 Glaxo Group Ltd 11 alpha-amino-androstane compound
JPS57203100A (en) * 1981-05-29 1982-12-13 Glaxo Group Ltd 11 alpha-amino-androstanes
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
FR2910002B1 (en) * 2006-12-13 2009-01-30 Sanofi Aventis Sa NOVEL METHOD FOR THE DIASTEREOSELECTIVE OBTAINING OF A PRIMARY CHIRAL AMINE ON A STEROID
JP2010037243A (en) * 2008-08-04 2010-02-18 Mitsubishi Rayon Co Ltd Method for producing norbornene lactone monomer
EP2766380B1 (en) 2011-10-14 2019-04-24 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
CN112472814A (en) 2012-01-23 2021-03-12 萨奇治疗股份有限公司 Neuroactive steroid formulations and methods of treating central nervous system disorders
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
PL2986624T3 (en) 2013-04-17 2020-11-16 Sage Therapeutics, Inc. 19-nor neuroactive steroids for methods of treatment
US9512165B2 (en) 2013-04-17 2016-12-06 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
DK3021852T3 (en) * 2013-07-19 2021-03-15 Sage Therapeutics Inc NEUROACTIVE STEROIDS, COMPOSITIONS AND USES
CA3235088A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SG10202009859YA (en) 2014-10-16 2020-11-27 Sage Therapeutics Inc Compositions and methods for treating cns disorders
EP3206493B1 (en) 2014-10-16 2020-05-06 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
EP3250210B1 (en) 2015-01-26 2020-12-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
ES2935476T3 (en) 2015-02-20 2023-03-07 Sage Therapeutics Inc Neuroactive steroids, compositions and uses thereof
CA3158448A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
DK3481845T3 (en) 2016-07-11 2023-11-27 Sage Therapeutics Inc C17, C20 AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
JP7065825B2 (en) 2016-07-11 2022-05-12 セージ セラピューティクス， インコーポレイテッド C7, C12, and C16 replacement neurostimulatory steroids and how to use them
CA3086189A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CA3120872A1 (en) 2018-12-05 2020-06-11 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
EP3990468A1 (en) * 2019-06-27 2022-05-04 Sage Therapeutics, Inc. Compounds for treating cns disorders
JP2022538300A (en) * 2019-06-27 2022-09-01 セージ セラピューティクス， インコーポレイテッド Compositions and methods for treating CNS disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2982775A (en) * 1957-05-06 1961-05-02 Schering Corp 11-oximino-, amino- and acylaminosteroids

Also Published As

Publication number Publication date
IE45276L (en) 1977-10-05
NZ183775A (en) 1979-12-11
NL7703667A (en) 1977-10-07
JPS52142056A (en) 1977-11-26
DK148677A (en) 1977-10-06
ZA772029B (en) 1978-11-29
FI771046A (en) 1977-10-06
FR2485020A1 (en) 1981-12-24
SE7703929L (en) 1978-10-27
FR2347382A1 (en) 1977-11-04
GB1581234A (en) 1980-12-10
LU77064A1 (en) 1979-01-18
IT1073232B (en) 1985-04-13
BE853227A (en) 1977-10-04
ES457507A1 (en) 1978-03-16
DE2715078A1 (en) 1977-10-13
IE45276B1 (en) 1982-07-28
AU517206B2 (en) 1981-07-16
AU2394277A (en) 1978-10-12
IL51816A (en) 1981-09-13
NO771197L (en) 1977-10-06
FR2347382B1 (en) 1982-01-08
IL51816A0 (en) 1977-06-30

Similar Documents

Publication Publication Date Title
PL197186A1 (en) METHOD OF MAKING STEROIDS
PL201286A1 (en) METHOD OF MAKING NEW 1-ARYLOXY-2-HYDROXY-3-ALKYLENE-AMINOPROPANE
PL195088A1 (en) METHOD OF PRODUCING N-PHOSPHONOMETHYLGLICINE
PL199798A1 (en) METHOD OF MAKING GAMMA-PYRONY
PL197372A1 (en) METHOD OF MAKING CANAMYCIN DERIVATIVES
PL198727A1 (en) METHOD OF REDUCING CEPHALSPORINE SULPHOXES
PL199298A1 (en) METHOD OF MAKING 2-BROMO-6-FLUORO-N-2-IMIDAZOLIDINYLIDENE-BENZAMINE
PL200534A1 (en) METHOD OF MAKING NEW OXADESTIACHALOSPORINES
PL200583A1 (en) METHOD OF MAKING NEW BENZOPIRANE DERIVATIVES
PL199633A1 (en) METHOD OF MAKING 5-M-TOLYLOXYURACYL
PL198878A1 (en) METHOD OF MAKING 2-CHLOROSULFINYLAZETHIDINONE DERIVATIVES
PL200605A1 (en) METHOD OF MAKING NEW METHIONINOENKEPHALIN DERIVATIVES
PL207237A1 (en) METHOD OF MAKING PREGNAN SERIES STEROIDS
PL202091A1 (en) METHOD OF MAKING GAMMA-PYRONOW
PL201133A1 (en) METHOD OF MAKING NEW PIRYDOBENZODWUAZEPINONOV
PL195267A1 (en) METHOD OF MAKING (2-KETOPYROLIDININE) -ALCANOCARBONAMIDE
PL201161A1 (en) METHOD OF MAKING NEW DERIVATIVES OF 9-CHLOROPREDISOLONE
PL197646A1 (en) METHOD OF MAKING 1-CARBAMYLURACYL DERIVATIVES
PL196061A1 (en) METHOD OF MAKING NEW DERIVATIVES OF INDOLYSIN
PL201883A1 (en) METHOD OF MAKING NEW TRANS-5A-ARYL-CHABENZAZEPINE DERIVATIVES
PL202697A1 (en) METHOD OF MAKING 2-BROMO-ALPHA-ERGOCRYPTIN
PL190443A1 (en) METHOD OF OBTAINING P-NITRODIPHENYLAMINE
PL196543A1 (en) METHOD OF MAKING NEW DERIVATIVES OF ASIRIDINE
PL192043A1 (en) METHOD OF MAKING POLINITRO-TESTS
PL96646B1 (en) METHOD OF MAKING ALKYL-BETA-DL-RIBOPYRANOSIDO